Drug Profile


Alternative Names: Adipose-derived stem and regenerative cell (ADRC) therapy - Cytori Therapeutics; Adipose-derived stem cells - Cytori Therapeutics; ADRCs - Cytori Therapeutics; Cytori Cell Therapy; ECCI-50; ECCO-50; ECCS-50; Habeo; Habeo Cell Therapy

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytori Therapeutics
  • Developer Assistance Publique - Hopitaux de Marseille; Cytori Therapeutics; Nagoya University
  • Class Skin disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Raynaud's disease; Scleroderma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Scleroderma; Urinary incontinence
  • Phase I Osteonecrosis

Most Recent Events

  • 28 Mar 2018 Cytori Therapeutics announces intention to submit application for marketing authorisation in Japan for Urinary incontinence
  • 28 Mar 2018 Nagoya University and Cytori Therapeutics complete enrolment in the phase III ADRESU trial for Urinary incontinence in Japan
  • 15 Feb 2018 Updated efficacy and adverse events data from the phase III STAR trial in Scleroderma released by Cytori Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top